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Sir,
We read with interest the recent guidelines for the management
of cystic fibrosis-associated liver disease (CFLD), particularly the
section addressing indications and dosing of ursodeoxycholic acid
(UDCA) [1]. The guidelines recommended the use ofUDCA, at an
initial dose of 20 mg/kg/day and as soon as the diagnosis of CFLD
is made, in order to delay disease progression. However, the use of
UDCA in all cholestatic diseases, includingCFLD, is controversial
and not as clear-cut as the recommendations suggest.
Ursodeoxycholic acid has been observed to reduce abnormal-
ities in liver biochemistry tests (such as GGT, AST and ALT).
However, it is well-recognised that liver biochemistry is a poor
and unreliable marker of the severity and progression of liver
disease, and progression can occur in the presence of normal liver
biochemistry markers [2–6]. In fact, there are no reliable markers
or predictors of early liver disease or of disease progression.
Furthermore, the diagnosis of CFLD is usually made after severe,
clinically significant liver disease with cirrhosis and portal
hypertension has already developed.
The consensus guidelines recommend the use of UDCA for all
individuals with CF who have at least two of the following:
hepatomegaly and/or splenomegaly; abnormal liver biochemistry
on at least 3 consecutive determinations over 12 months (after
excluding other causes of liver disease); and ultrasonographic
evidence of hepato-biliary involvement (increased and/or hetero-
geneous echogenicity, irregular margins, nodularity, and bile duct
dilatation) or portal hypertension [1]. Severe CFLD with portal
hypertension occurs in only 3–5% of CF patients, suggesting that
the majority of CF patients with abnormalities in liver
biochemistry tests do not progress to clinically significant
CFLD [4]. Furthermore, there is no evidence that persistent
abnormalities in liver biochemistry, is a predictor of severe liver
disease. Increased and/or heterogeneous echogenicity of the liver
is non-specific and may be due to steatosis rather than fibrosis/
cirrhosis [7]. In a prospective study of suspected CFLD patients
with abnormal clinical, biochemical (raised ALT for 6 months)
and ultrasound findings, neither clinical examination, serumALT
levels nor ultrasound findings predicted presence of liver fibrosis
or the development of portal hypertension [6]. Thus, if the
aforementioned criteria are followed it is likely that the majority
of patients that are subjected to UCDA are unlikely to develop
clinically significant CFLD. Conversely, patients not fitting with1569-1993/$ - see front matter © 2011 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2011.08.002the suggested diagnostic criteria may still be at risk of developing
clinically significant liver disease.
Treatment of CFLD with UDCA was recommended in the
North American consensus guideline published more than a
decade ago [8]. Although that guideline recognised that there was
no clinically proven short- or long-term benefit using UDCA in
CFLD, the recommendation was on the basis of lack of harm and
potential benefit inCFLDdue to the reported benefits ofUDCA in
another liver disease of primary biliary cirrhosis. The recently
published guidelines also acknowledge that there is no clinically
proven benefit from UDCA therapy in CFLD; however, we
believe that a more detailed discussion of potential adverse effects
and dosage is necessary, given recent experience with UDCA in
other cholestatic conditions. UDCA therapy, previously recom-
mended in primary sclerosing cholangitis and primary biliary
cirrhosis, has recently been called into question [5,9]. We believe
that attention should be paid to the findings of a well conducted,
randomised double-blind placebo-controlled trial of high dose
(28–30 mg/kg/day) UDCA in primary sclerosing cholangitis.
Although this study showed improvement in liver biochemistry
on UDCA therapy, it was terminated early by the National
Institutes of Health's Data Monitoring and Safety Board due to
increased risk of major adverse events (death and liver
transplantation) in the UDCA treatment arm in comparison with
the placebo arm [5]. A higher dose ofUDCAwas used in this PSC
study than the recommended initial dose of 20 mg/kg/day stated
in the CFLD recommendations. However, the guidelines also
recommended the increase in UDCA dose “if necessary”
depending on liver biochemistry results. Of note, patients need
not have abnormalities in liver biochemistry tests to fulfil the
consensus definition of CFLD, and intestinal absorption of
UDCAmay vary among patients with pancreatic insufficient CF.
Lower doses of UDCA have yet to be evaluated for long term
safety and efficacy in CFLD.
The role and use of UDCA is controversial and the evidence
for and against its use requires critical appraisal, especially in best
practise guidance/guidelines written by expert hepatologists.
Simply put, at present, there are no convincing data to
demonstrate that UDCA is efficacious or harmful in CFLD.
Future studies addressing the aforementioned issues are urgently
needed before firm recommendations for or against the use of
UDCA can be made.
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